IL17A and psoriasis: Actually, recent studies revealed that in psoriasis, a common autoimmune disorder of the skin, the ROCK2 inhibitor KD025 downregulated IL-17 levels, and thus TH17 immune response, with additional upregulation of IL-10 and subsequent clinical improvement after 12 weeks of treatment (Zanin-Zhorov et al., 2017).